MedTrace Logo

DBT and Escitalopram in Borderline Personality Disorder

NCT00255554 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2005-11-21

No results posted yet for this study

Summary

Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Conditions

  • Borderline Personality Disorder

Interventions

BEHAVIORAL

Dialectical Behavioral Therapy

DRUG

Escitalopram

Sponsors & Collaborators

  • Bronx VA Medical Center

    lead FED

Principal Investigators

  • Marianne Goodman, MD · Bronx VA Medical Center/Mount Sinai School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255554 on ClinicalTrials.gov